IL299924B2 - CFTR regulators and methods of using them - Google Patents

CFTR regulators and methods of using them

Info

Publication number
IL299924B2
IL299924B2 IL299924A IL29992423A IL299924B2 IL 299924 B2 IL299924 B2 IL 299924B2 IL 299924 A IL299924 A IL 299924A IL 29992423 A IL29992423 A IL 29992423A IL 299924 B2 IL299924 B2 IL 299924B2
Authority
IL
Israel
Prior art keywords
compound
och
hydrogen
ochch
halogen
Prior art date
Application number
IL299924A
Other languages
English (en)
Hebrew (he)
Other versions
IL299924B1 (en
IL299924A (en
Inventor
Alan Verkman
Marc H Levin
Onur Cil
Original Assignee
Univ California
Alan Verkman
Marc H Levin
Onur Cil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Alan Verkman, Marc H Levin, Onur Cil filed Critical Univ California
Publication of IL299924A publication Critical patent/IL299924A/en
Publication of IL299924B1 publication Critical patent/IL299924B1/en
Publication of IL299924B2 publication Critical patent/IL299924B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
IL299924A 2015-12-24 2016-12-23 CFTR regulators and methods of using them IL299924B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24
PCT/US2016/068561 WO2017112947A1 (en) 2015-12-24 2016-12-23 Cftr regulators and methods of use thereof

Publications (3)

Publication Number Publication Date
IL299924A IL299924A (en) 2023-03-01
IL299924B1 IL299924B1 (en) 2024-09-01
IL299924B2 true IL299924B2 (en) 2025-01-01

Family

ID=59091233

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299924A IL299924B2 (en) 2015-12-24 2016-12-23 CFTR regulators and methods of using them
IL260210A IL260210B2 (en) 2015-12-24 2018-06-21 cftr regulators and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL260210A IL260210B2 (en) 2015-12-24 2018-06-21 cftr regulators and methods of using them

Country Status (17)

Country Link
US (2) US20190031630A1 (pl)
EP (1) EP3394083B9 (pl)
JP (1) JP6894902B2 (pl)
KR (1) KR102723194B1 (pl)
CN (1) CN108699107B (pl)
AU (2) AU2016377782B2 (pl)
BR (1) BR112018012927A2 (pl)
CA (1) CA3009531A1 (pl)
CL (1) CL2018001714A1 (pl)
CO (1) CO2018007239A2 (pl)
ES (1) ES2901002T3 (pl)
IL (2) IL299924B2 (pl)
PL (1) PL3394083T3 (pl)
PT (1) PT3394083T (pl)
RU (1) RU2742934C2 (pl)
WO (1) WO2017112947A1 (pl)
ZA (1) ZA201804228B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102733897B1 (ko) 2015-12-24 2024-11-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
US11839616B2 (en) * 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
MX2023004712A (es) 2020-10-23 2023-05-09 Ildong Pharmaceutical Co Ltd Compuestos moduladores del cftr, composiciones y usos de estos.
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Xa 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
AP2005003292A0 (en) * 2002-09-30 2005-06-30 Univ California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7977322B2 (en) * 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EA021904B1 (ru) 2008-03-05 2015-09-30 Мерк Патент Гмбх Производные хиноксалинона в качестве стимуляторов секреции инсулина, способы их получения и их применение для лечения диабета
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
TWI450891B (zh) * 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
WO2015138909A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters

Also Published As

Publication number Publication date
CA3009531A1 (en) 2017-06-29
WO2017112947A1 (en) 2017-06-29
BR112018012927A2 (pt) 2018-12-11
CN108699107B (zh) 2022-05-10
KR20180101415A (ko) 2018-09-12
RU2018126959A3 (pl) 2020-08-20
AU2021257948A1 (en) 2021-11-25
CN108699107A (zh) 2018-10-23
ES2901002T3 (es) 2022-03-21
AU2016377782B2 (en) 2021-07-29
RU2742934C2 (ru) 2021-02-11
US11192869B2 (en) 2021-12-07
PL3394083T3 (pl) 2022-01-17
RU2018126959A (ru) 2020-01-24
KR102723194B1 (ko) 2024-10-28
IL260210A (en) 2018-07-31
CO2018007239A2 (es) 2018-07-19
CL2018001714A1 (es) 2018-10-26
ES2901002T9 (es) 2022-06-20
EP3394083A4 (en) 2019-09-04
EP3394083B9 (en) 2022-04-27
US20200140402A1 (en) 2020-05-07
PT3394083T (pt) 2021-12-07
NZ743720A (en) 2024-08-30
ZA201804228B (en) 2020-09-30
US20190031630A1 (en) 2019-01-31
JP2018538354A (ja) 2018-12-27
AU2016377782A1 (en) 2018-07-12
EP3394083B1 (en) 2021-09-01
IL299924B1 (en) 2024-09-01
IL260210B2 (en) 2023-06-01
AU2021257948B2 (en) 2023-11-30
JP6894902B2 (ja) 2021-06-30
EP3394083A1 (en) 2018-10-31
IL299924A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
IL299924B2 (en) CFTR regulators and methods of using them
IL271631A (en) Deuterium compounds and their use
WO2013006864A3 (en) Treating cancer with hsp90 inhibitory compounds
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
MX2022002108A (es) Metodo para tratar canceres asociados con kras.
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
WO2014144761A3 (en) Increasing specificity for rna-guided genome editing
WO2014152389A8 (en) Imaging agent for detection of diseased cells
WO2016096174A8 (en) Cyclic dinucleotides for cytokine induction
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
MX2015012743A (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
UA116923C2 (uk) (6S,9aS)-N-БЕНЗИЛ-6-[(4-ГІДРОКСИФЕНІЛ)МЕТИЛ]-4,7-ДІОКСО-8-({6-[3-(ПІПЕРАЗИН-1-ІЛ)АЗЕТИДИН-1-ІЛ]ПІРИДИН-2-ІЛ}МЕТИЛ)-2-(ПРОП-2-ЕН-1-ІЛ)-ОКТАГІДРО-1H-ПІРАЗИНО[2,1-c][1,2,4]ТРИАЗИН-1-КАРБОКСАМІДНА СПОЛУКА
MX2016009974A (es) Derivados de diaminopirimidina bencensulfona y sus usos.
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
MX384244B (es) 4-fenilpiperidinas sustituidas, su preparacion y uso.
EA201691194A1 (ru) Стимуляторы ргц
EA201690127A1 (ru) Состав на основе ингибиторов syk
EP3943188A3 (en) Design, synthesis and characterization of metal organic frameworks
WO2016176473A8 (en) Apelin receptor agonists and methods of use thereof
JP2013532130A5 (pl)
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
PH12017502388A1 (en) 1,4-di-substituted imidazole derivative
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2021004474A (es) Compuestos que contienen deuterio.